From Emollients to Biologicals: Targeting Atopic Dermatitis

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients’ lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvati, Lorenzo, Cosmi, Lorenzo, Annunziato, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508966/
https://www.ncbi.nlm.nih.gov/pubmed/34638722
http://dx.doi.org/10.3390/ijms221910381
_version_ 1784582222996570112
author Salvati, Lorenzo
Cosmi, Lorenzo
Annunziato, Francesco
author_facet Salvati, Lorenzo
Cosmi, Lorenzo
Annunziato, Francesco
author_sort Salvati, Lorenzo
collection PubMed
description Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients’ lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current description of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs.
format Online
Article
Text
id pubmed-8508966
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85089662021-10-13 From Emollients to Biologicals: Targeting Atopic Dermatitis Salvati, Lorenzo Cosmi, Lorenzo Annunziato, Francesco Int J Mol Sci Review Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients’ lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is characterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current description of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs. MDPI 2021-09-26 /pmc/articles/PMC8508966/ /pubmed/34638722 http://dx.doi.org/10.3390/ijms221910381 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Salvati, Lorenzo
Cosmi, Lorenzo
Annunziato, Francesco
From Emollients to Biologicals: Targeting Atopic Dermatitis
title From Emollients to Biologicals: Targeting Atopic Dermatitis
title_full From Emollients to Biologicals: Targeting Atopic Dermatitis
title_fullStr From Emollients to Biologicals: Targeting Atopic Dermatitis
title_full_unstemmed From Emollients to Biologicals: Targeting Atopic Dermatitis
title_short From Emollients to Biologicals: Targeting Atopic Dermatitis
title_sort from emollients to biologicals: targeting atopic dermatitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508966/
https://www.ncbi.nlm.nih.gov/pubmed/34638722
http://dx.doi.org/10.3390/ijms221910381
work_keys_str_mv AT salvatilorenzo fromemollientstobiologicalstargetingatopicdermatitis
AT cosmilorenzo fromemollientstobiologicalstargetingatopicdermatitis
AT annunziatofrancesco fromemollientstobiologicalstargetingatopicdermatitis

Ejemplares similares